The initial hormone receptor/HER2 subtype is the main determinator of subtype discordance in advanced breast cancer : a study of the SONABRE registry
© 2022. The Author(s)..
PURPOSE: The hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) are the main parameters in guiding systemic treatment choices in breast cancer, but can change during the disease course. This study aims to evaluate the biopsy rate and receptor subtype discordance rate in patients diagnosed with advanced breast cancer (ABC).
METHODS: Patients diagnosed with ABC in seven hospitals in 2007-2018 were selected from the SOutheast Netherlands Advanced BREast cancer (SONABRE) registry. Multivariable logistic regression analyses were performed to identify factors influencing biopsy and discordance rates.
RESULTS: Overall, 60% of 2854 patients had a biopsy of a metastatic site at diagnosis. One of the factors associated with a reduced biopsy rate was the HR + /HER2 + primary tumor subtype (versus HR + /HER2- subtype: OR = 0.68; 95% CI: 0.51-0.90). Among the 748 patients with a biopsy of the primary tumor and a metastatic site, the overall receptor discordance rate was 18%. This was the highest for the HR + /HER2 + primary tumor subtype, with 55%. In 624 patients with metachronous metastases, the HR + /HER2 + subtype remained the only predictor significantly related to a higher discordance rate, irrespective of prior (neo-)adjuvant therapies (OR = 7.49; 95% CI: 3.69-15.20).
CONCLUSION: The HR + /HER2 + subtype has the highest discordance rate, but the lowest biopsy rate of all four receptor subtypes. Prior systemic therapy was not independently related to subtype discordance. This study highlights the importance of obtaining a biopsy of metastatic disease, especially in the HR + /HER2 + subtype to determine the most optimal treatment strategy.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Zur Gesamtaufnahme - volume:192 |
---|---|
Enthalten in: |
Breast cancer research and treatment - 192(2022), 2 vom: 13. Apr., Seite 331-342 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Meegdes, Marissa [VerfasserIn] |
---|
Links: |
---|
Themen: |
Biomarkers, Tumor |
---|
Anmerkungen: |
Date Completed 18.03.2022 Date Revised 31.05.2022 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1007/s10549-021-06472-5 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM335598730 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM335598730 | ||
003 | DE-627 | ||
005 | 20231225230221.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s10549-021-06472-5 |2 doi | |
028 | 5 | 2 | |a pubmed24n1118.xml |
035 | |a (DE-627)NLM335598730 | ||
035 | |a (NLM)35025003 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Meegdes, Marissa |e verfasserin |4 aut | |
245 | 1 | 4 | |a The initial hormone receptor/HER2 subtype is the main determinator of subtype discordance in advanced breast cancer |b a study of the SONABRE registry |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 18.03.2022 | ||
500 | |a Date Revised 31.05.2022 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2022. The Author(s). | ||
520 | |a PURPOSE: The hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) are the main parameters in guiding systemic treatment choices in breast cancer, but can change during the disease course. This study aims to evaluate the biopsy rate and receptor subtype discordance rate in patients diagnosed with advanced breast cancer (ABC) | ||
520 | |a METHODS: Patients diagnosed with ABC in seven hospitals in 2007-2018 were selected from the SOutheast Netherlands Advanced BREast cancer (SONABRE) registry. Multivariable logistic regression analyses were performed to identify factors influencing biopsy and discordance rates | ||
520 | |a RESULTS: Overall, 60% of 2854 patients had a biopsy of a metastatic site at diagnosis. One of the factors associated with a reduced biopsy rate was the HR + /HER2 + primary tumor subtype (versus HR + /HER2- subtype: OR = 0.68; 95% CI: 0.51-0.90). Among the 748 patients with a biopsy of the primary tumor and a metastatic site, the overall receptor discordance rate was 18%. This was the highest for the HR + /HER2 + primary tumor subtype, with 55%. In 624 patients with metachronous metastases, the HR + /HER2 + subtype remained the only predictor significantly related to a higher discordance rate, irrespective of prior (neo-)adjuvant therapies (OR = 7.49; 95% CI: 3.69-15.20) | ||
520 | |a CONCLUSION: The HR + /HER2 + subtype has the highest discordance rate, but the lowest biopsy rate of all four receptor subtypes. Prior systemic therapy was not independently related to subtype discordance. This study highlights the importance of obtaining a biopsy of metastatic disease, especially in the HR + /HER2 + subtype to determine the most optimal treatment strategy | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Biopsy | |
650 | 4 | |a Breast cancer | |
650 | 4 | |a HER2 receptor | |
650 | 4 | |a Hormone receptor | |
650 | 4 | |a Metastatic disease | |
650 | 4 | |a Subtype | |
650 | 7 | |a Biomarkers, Tumor |2 NLM | |
650 | 7 | |a Hormones |2 NLM | |
650 | 7 | |a Receptors, Progesterone |2 NLM | |
650 | 7 | |a ERBB2 protein, human |2 NLM | |
650 | 7 | |a EC 2.7.10.1 |2 NLM | |
650 | 7 | |a Receptor, ErbB-2 |2 NLM | |
650 | 7 | |a EC 2.7.10.1 |2 NLM | |
700 | 1 | |a Ibragimova, Khava I E |e verfasserin |4 aut | |
700 | 1 | |a Lobbezoo, Dorien J A |e verfasserin |4 aut | |
700 | 1 | |a Vriens, Ingeborg J H |e verfasserin |4 aut | |
700 | 1 | |a Kooreman, Loes F S |e verfasserin |4 aut | |
700 | 1 | |a Erdkamp, Frans L G |e verfasserin |4 aut | |
700 | 1 | |a Dercksen, M Wouter |e verfasserin |4 aut | |
700 | 1 | |a Vriens, Birgit E P J |e verfasserin |4 aut | |
700 | 1 | |a Aaldering, Kirsten N A |e verfasserin |4 aut | |
700 | 1 | |a Pepels, Manon J A E |e verfasserin |4 aut | |
700 | 1 | |a van de Winkel, Linda M H |e verfasserin |4 aut | |
700 | 1 | |a Tol, Jolien |e verfasserin |4 aut | |
700 | 1 | |a Heijns, Joan B |e verfasserin |4 aut | |
700 | 1 | |a van de Wouw, Agnes J |e verfasserin |4 aut | |
700 | 1 | |a Peters, Natascha A J B |e verfasserin |4 aut | |
700 | 1 | |a Hochstenbach-Waelen, Ananda |e verfasserin |4 aut | |
700 | 1 | |a Smidt, Marjolein L |e verfasserin |4 aut | |
700 | 1 | |a Geurts, Sandra M E |e verfasserin |4 aut | |
700 | 1 | |a Tjan-Heijnen, Vivianne C G |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Breast cancer research and treatment |d 1992 |g 192(2022), 2 vom: 13. Apr., Seite 331-342 |w (DE-627)NLM01302132X |x 1573-7217 |7 nnns |
773 | 1 | 8 | |g volume:192 |g year:2022 |g number:2 |g day:13 |g month:04 |g pages:331-342 |
856 | 4 | 0 | |u http://dx.doi.org/10.1007/s10549-021-06472-5 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 192 |j 2022 |e 2 |b 13 |c 04 |h 331-342 |